Irsu Injection contains Iron Sucrose (100mg/5ml) and is indicated for the treatment of iron deficiency anemia, particularly in patients with chronic kidney disease undergoing hemodialysis or those who are intolerant or unresponsive to oral iron therapy. Iron Sucrose is a complex of polynuclear iron(III)-hydroxide in sucrose, designed for intravenous administration to replenish iron stores efficiently. The injection facilitates the synthesis of hemoglobin and the restoration of normal erythropoiesis by providing bioavailable iron directly to the reticuloendothelial system. Irsu Injection is administered under medical supervision, with dosage tailored to individual patient requirements based on hemoglobin levels, iron parameters, and clinical response. Common adverse effects may include hypotension, nausea, dizziness, and injection site reactions, though serious hypersensitivity reactions are rare. Caution is advised in patients with known hypersensitivity to iron sucrose or any component of the formulation, active infections, or iron overload conditions. Regular monitoring of serum ferritin and transferrin saturation is recommended to avoid iron overload. Irsu Injection offers a safe and effective parenteral iron replacement option, improving patient outcomes where oral iron supplementation is inadequate or contraindicated.